Early biomarkers of clinical-diffusion mismatch in acute ischemic stroke

Stroke

Volumn 42, Issue 10, 2011, Pages 2813-2818

  Rodríguez Yáñez, Manuel ^a   Sobrino, Tomás ^a   Arias, Susana ^a   Vázquez Herrero, Fernando ^a   Brea, David ^a   Blanco, Miguel ^a   Leira, Rogelio ^a   Castellanos, Mar ^b   Serena, Joaquín ^b   Vivancos, José ^c   Dávalos, Antonio ^d   Castillo, José ^a  

^a Instituto de Salud Carlos III   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

biomarkers; clinical diffusion mismatch; ischemic stroke

Indexed keywords

ASPARTIC ACID; FIBRONECTIN; GELATINASE B; GLUTAMIC ACID; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE DISEASE; AGED; ARTICLE; BLOOD SAMPLING; BRAIN DAMAGE; BRAIN ISCHEMIA; BRAIN SIZE; CLINICAL DIFFUSION MISMATCH; DIFFUSION WEIGHTED IMAGING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GLUTAMIC ACID; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROSPECTIVE STUDIES; STROKE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 80053309532     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.614503     Document Type: Article

References (29)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020. (Pubitemid 32336306)
3. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al; DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517. (Pubitemid 44871793)
4. Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, et al; DEFUSE investigators. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion-and diffusion-weighted imaging in the DEFUSE study. Radiology. 2008;249:614-623.
5. Cvoro V, Marshall I, Armitage PA, Bastin ME, Carpenter T, Rivers CS, et al. MR diffusion and perfusion parameters: relationship to metabolites in acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2010;81: 185-191.
6. Rivers CS, Wardlaw JM, Armitage PA, Bastin ME, Carpenter TK, Cvoro V, et al. Do acute diffusion-and perfusion-weighted MRI lesions identify final infarct volume in ischemic stroke? Stroke. 2006;37:98-104. (Pubitemid 43732055)
7. Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, et al. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke. 2010; 41:e25-e33.
8. Dávalos A, Blanco M, Pedraza S, Leira R, Castellanos M, Pumar JM, et al. The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction. Neurology. 2004;62:2187-2192. (Pubitemid 38787773)
9. Prosser J, Butcher K, Allport L, Parsons M, MacGregor L, Desmond P, et al. Clinical-diffusion mismatch predicts the putative penumbra with high specificity. Stroke. 2005;36:1700-1704. (Pubitemid 41098765)
10. Tei H, Uchiyama S, Usui T. Clinical-diffusion mismatch defined by NIHSS and ASPECTS in non-lacunar anterior circulation infarction. J Neurol. 2007;254:340-346. (Pubitemid 46399196)
11. Janjua N, El-Gengaihy A, Pile-Spellman J, Qureshi AI. Late endovascular revascularization in acute ischemic stroke based on clinical-diffusion mismatch. AJNR Am J Neuroradiol. 2009;30:1024-1027.
12. Terasawa Y, Kimura K, Iguchi Y, Kobayashi K, Aoki J, Shibazaki K, et al. Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke? J Neurol Neurosurg Psychiatry. 2010;81:864-868.
13. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Cerebrovasc Dis. 2008;25:457-507.
14. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007; 369:275-282. (Pubitemid 46138121)
15. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. (Pubitemid 23014379)
16. White JA, Hart RJ, Fry JC. An evaluation of the Waters Pico-Tag system for the amino-acid analysis of food materials. J Automat Chem. 1986;8: 170-177. (Pubitemid 17168319)
17. Sunshine JL, Tarr RW, Lanzieri CF, Landis DM, Selman WR, Lewin JS. Hyperacute stroke: ultrafast MR imaging to triage patients prior to therapy. Radiology. 1999;212:325-332. (Pubitemid 29356548)
18. Schlaug G, Benfield A, Baird AE, Siewert B, Lövblad KO, Parker RA, et al. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology. 1999;53:1528-1537. (Pubitemid 29491949)
19. Ebinger M, Iwanaga T, Prosser JF, De Silva DA, Christensen S, Collins M, et al; EPITHET Investigators. Clinical-diffusion mismatch and benefit from thrombolysis 3 to 6 hours after acute stroke. Stroke. 2009; 40:2572-2574.
20. Lansberg MG, Thijs VN, Hamilton S, Schlaug G, Bammer R, Kemp S, et al; DEFUSE Investigators. Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE. Stroke. 2007;38: 1826-1830. (Pubitemid 46847254)
21. Beamer NB, Coull BM, Clark WM, Hazel JS, Silberger JR. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995; 37:800-805.
22. Tarkowski E, Rosengren L, Blomstrand C, Wikkelsö C, Jensen C, Ekholm S, et al. Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke. 1995;26:1393-1398.
23. Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994;122:135-139. (Pubitemid 24097260)
24. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31: 2325-2329.
25. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671-675. (Pubitemid 36307391)
26. Castillo J, Davalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 1997;349:79-83. (Pubitemid 27023423)
27. Castellanos M, Sobrino T, Pedraza S, Moldes O, Pumar JM, Silva Y, et al. High plasma glutamate concentrations are associated with infarct growth in acute ischemic stroke. Neurology. 2008;71:1862-1868.
28. Brea D, Sobrino T, Blanco M, Cristobo I, Rodríguez-González R, Rodríguez-Yañez M, et al. Temporal profile and clinical significance of serum neuron-specific enolase and S100 in ischemic and hemorrhagic stroke. Clin Chem Lab Med. 2009;47:1513-1518.
29. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003;34:40-46.